Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 228

1.

SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019).

Dómine M, Moran T, Isla D, Martí JL, Sullivan I, Provencio M, Olmedo ME, Ponce S, Blasco A, Cobo M.

Clin Transl Oncol. 2020 Feb;22(2):245-255. doi: 10.1007/s12094-020-02295-w. Epub 2020 Feb 10.

PMID:
32040815
2.

IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY.

Travis WD, Dacic S, Wistuba I, Sholl L, Adusumilli P, Bubendorf L, Bunn P, Cascone T, Chaft J, Chen G, Chou TY, Cooper W, Erasmus JJ, Ferreira CG, Goo JM, Heymach J, Hirsch FR, Horinouchi H, Kerr K, Kris M, Jain D, Kim YT, Lopez-Rios F, Lu S, Mitsudomi T, Moreira A, Motoi N, Nicholson AG, Oliveira R, Papotti M, Pastorino U, Paz-Ares L, Pelosi G, Poleri C, Provencio M, Roden AC, Scagliotti G, Swisher SG, Thunnissen E, Tsao MS, Vansteenkiste J, Weder W, Yatabe Y.

J Thorac Oncol. 2020 Jan 28. pii: S1556-0864(20)30026-5. doi: 10.1016/j.jtho.2020.01.005. [Epub ahead of print] Review.

PMID:
32004713
3.

Neoadjuvant treatment with tyrosine kinase inhibitors in patients with resectable non-small cell lung cancer.

Franco F, Provencio M.

J Thorac Dis. 2019 Oct;11(10):4092-4095. doi: 10.21037/jtd.2019.09.68. No abstract available.

4.

Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study).

Provencio M, Carcereny E, Rodríguez-Abreu D, López-Castro R, Guirado M, Camps C, Bosch-Barrera J, García-Campelo R, Ortega-Granados AL, González-Larriba JL, Casal-Rubio J, Domine M, Massutí B, Sala MÁ, Bernabé R, Oramas J, Del Barco E.

Transl Lung Cancer Res. 2019 Aug;8(4):461-475. doi: 10.21037/tlcr.2019.08.05.

5.

Next-generation sequencing for tumor mutation quantification using liquid biopsies.

Provencio M, Pérez-Barrios C, Barquin M, Calvo V, Franco F, Sánchez E, Sánchez R, Marsden D, Cristóbal Sánchez J, Martin Acosta P, Laza-Briviesca R, Cruz-Bermúdez A, Romero A.

Clin Chem Lab Med. 2020 Jan 28;58(2):306-313. doi: 10.1515/cclm-2019-0745.

PMID:
31469650
6.

Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized phase II (RENO study).

Isla D, De Las Peñas R, Insa A, Marsé R, Martínez-Banaclocha N, Mut P, Morán T, Sala MÁ, Massuti B, Ortega AL, Jurado JM, Gómez-Codina J, Diz P, Artal Á, Gutiérrez V, Vázquez MF, Viñolas N, Maestu I, Camps C, Álvarez R, de Mon Soto MÁ, Ponce S, Provencio M.

Lung Cancer. 2019 Sep;135:161-168. doi: 10.1016/j.lungcan.2018.11.041. Epub 2018 Dec 1.

PMID:
31446990
7.

Residential radon, genetic polymorphisms in DNA damage and repair-related.

Lorenzo-González M, Ruano-Ravina A, Torres-Durán M, Kelsey KT, Provencio M, Parente-Lamelas I, Leiro-Fernández V, Vidal-García I, Castro-Añón O, Martínez C, Golpe-Gómez A, Torres-Español M, Abal-Arca J, Montero-Martínez C, Fernández-Villar A, Barros-Dios JM.

Lung Cancer. 2019 Sep;135:10-15. doi: 10.1016/j.lungcan.2019.07.003. Epub 2019 Jul 4.

PMID:
31446980
8.

ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer.

Marinis F, Wu YL, de Castro G Jr, Chang GC, Chen YM, Cho BC, Freitas HC, Jiang L, Kim SW, Martin C, Metro G, Provencio M, Vansteenkiste J, Vicente D, Zhou Q, Miranda MF, Bakker NA, Rigas JR, Cheema PK.

Future Oncol. 2019 Sep;15(26):3003-3014. doi: 10.2217/fon-2019-0324. Epub 2019 Jul 24.

PMID:
31339357
9.

Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance.

Zugazagoitia J, Gómez-Rueda A, Jantus-Lewintre E, Isla D, Camps C, Ramos I, Trigo JM, Bernabé R, Juan-Vidal O, Sanchez-Torres JM, García-Campelo R, Provencio M, Felip E, de Castro J, Faull I, Lanman RB, Ponce-Aix S, Paz-Ares L, Garrido P.

Lung Cancer. 2019 Aug;134:72-78. doi: 10.1016/j.lungcan.2019.05.032. Epub 2019 May 30.

PMID:
31319999
10.

Immune checkpoint inhibitor treatment in patients with oncogene- addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion.

Berghoff AS, Bellosillo B, Caux C, de Langen A, Mazieres J, Normanno N, Preusser M, Provencio M, Rojo F, Wolf J, Zielinski CC.

ESMO Open. 2019 Jun 17;4(3):e000498. doi: 10.1136/esmoopen-2019-000498. eCollection 2019. Review.

11.

Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial.

Reck M, Schenker M, Lee KH, Provencio M, Nishio M, Lesniewski-Kmak K, Sangha R, Ahmed S, Raimbourg J, Feeney K, Corre R, Franke FA, Richardet E, Penrod JR, Yuan Y, Nathan FE, Bhagavatheeswaran P, DeRosa M, Taylor F, Lawrance R, Brahmer J.

Eur J Cancer. 2019 Jul;116:137-147. doi: 10.1016/j.ejca.2019.05.008. Epub 2019 Jun 11.

12.

Multidisciplinary consensus statement on the clinical management of patients with stage III non-small cell lung cancer.

Majem M, Hernández-Hernández J, Hernando-Trancho F, Rodríguez de Dios N, Sotoca A, Trujillo-Reyes JC, Vollmer I, Delgado-Bolton R, Provencio M.

Clin Transl Oncol. 2020 Jan;22(1):21-36. doi: 10.1007/s12094-019-02134-7. Epub 2019 Jun 6.

PMID:
31172444
13.

Healthcare resource utilization and associated cost analysis of the PROCLAIM study in patients with stage III non-small-cell lung cancer.

Govindan R, Senan S, Dickgreber N, Provencio M, Wu YL, Syrigos K, Parente B, Wilson M, Ziemiecki R, Chouaki N, Hossain A, San Antonio B, Winfree K, Vokes EE.

Curr Med Res Opin. 2019 Oct;35(10):1761-1767. doi: 10.1080/03007995.2019.1623185. Epub 2019 Jul 5.

PMID:
31125266
14.

Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study.

Ramchandren R, Domingo-Domènech E, Rueda A, Trněný M, Feldman TA, Lee HJ, Provencio M, Sillaber C, Cohen JB, Savage KJ, Willenbacher W, Ligon AH, Ouyang J, Redd R, Rodig SJ, Shipp MA, Sacchi M, Sumbul A, Armand P, Ansell SM.

J Clin Oncol. 2019 Aug 10;37(23):1997-2007. doi: 10.1200/JCO.19.00315. Epub 2019 May 21.

PMID:
31112476
15.

Genetic Variants Associated With Cancer Therapy-Induced Cardiomyopathy.

Garcia-Pavia P, Kim Y, Restrepo-Cordoba MA, Lunde IG, Wakimoto H, Smith AM, Toepfer CN, Getz K, Gorham J, Patel P, Ito K, Willcox JA, Arany Z, Li J, Owens AT, Govind R, Nuñez B, Mazaika E, Bayes-Genis A, Walsh R, Finkelman B, Lupon J, Whiffin N, Serrano I, Midwinter W, Wilk A, Bardaji A, Ingold N, Buchan R, Tayal U, Pascual-Figal DA, de Marvao A, Ahmad M, Garcia-Pinilla JM, Pantazis A, Dominguez F, John Baksi A, O'Regan DP, Rosen SD, Prasad SK, Lara-Pezzi E, Provencio M, Lyon AR, Alonso-Pulpon L, Cook SA, DePalma SR, Barton PJR, Aplenc R, Seidman JG, Ky B, Ware JS, Seidman CE.

Circulation. 2019 Jul 2;140(1):31-41. doi: 10.1161/CIRCULATIONAHA.118.037934. Epub 2019 Apr 16.

16.

Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.

Michels S, Massutí B, Schildhaus HU, Franklin J, Sebastian M, Felip E, Grohé C, Rodriguez-Abreu D, Abdulla DSY, Bischoff H, Brandts C, Carcereny E, Corral J, Dingemans AC, Pereira E, Fassunke J, Fischer RN, Gardizi M, Heukamp L, Insa A, Kron A, Menon R, Persigehl T, Reck M, Riedel R, Rothschild SI, Scheel AH, Scheffler M, Schmalz P, Smit EF, Limburg M, Provencio M, Karachaliou N, Merkelbach-Bruse S, Hellmich M, Nogova L, Büttner R, Rosell R, Wolf J.

J Thorac Oncol. 2019 Jul;14(7):1266-1276. doi: 10.1016/j.jtho.2019.03.020. Epub 2019 Apr 9.

PMID:
30978502
17.

Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.

Sequist LV, Gray JE, Harb WA, Lopez-Chavez A, Doebele RC, Modiano MR, Jackman DM, Baggstrom MQ, Atmaca A, Felip E, Provencio M, Cobo M, Adiwijaya B, Kuesters G, Kamoun WS, Andreas K, Pipas JM, Santillana S, Cho BC, Park K, Shepherd FA.

Oncologist. 2019 Aug;24(8):1095-1102. doi: 10.1634/theoncologist.2018-0695. Epub 2019 Apr 11.

18.

Lung cancer and residential radon in never-smokers: A pooling study in the Northwest of Spain.

Lorenzo-González M, Ruano-Ravina A, Torres-Durán M, Kelsey KT, Provencio M, Parente-Lamelas I, Leiro-Fernández V, Vidal-García I, Castro-Añón O, Martínez C, Golpe-Gómez A, Zapata-Cachafeiro M, Piñeiro-Lamas M, Pérez-Ríos M, Abal-Arca J, Montero-Martínez C, Fernández-Villar A, Barros-Dios JM.

Environ Res. 2019 May;172:713-718. doi: 10.1016/j.envres.2019.03.011. Epub 2019 Mar 6.

PMID:
30903971
19.

Consensus on the use of immune-related response criteria to evaluate the efficacy of immunotherapy in non-small cell lung cancer.

Provencio M, Carcereny E, Artal Á.

Clin Transl Oncol. 2019 Nov;21(11):1464-1471. doi: 10.1007/s12094-019-02072-4. Epub 2019 Mar 22.

PMID:
30903517
20.

Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1α in NSCLC which can be overcome by OXPHOS inhibition.

Cruz-Bermúdez A, Laza-Briviesca R, Vicente-Blanco RJ, García-Grande A, Coronado MJ, Laine-Menéndez S, Palacios-Zambrano S, Moreno-Villa MR, Ruiz-Valdepeñas AM, Lendinez C, Romero A, Franco F, Calvo V, Alfaro C, Acosta PM, Salas C, Garcia JM, Provencio M.

Free Radic Biol Med. 2019 May 1;135:167-181. doi: 10.1016/j.freeradbiomed.2019.03.009. Epub 2019 Mar 14.

21.

Applying Data Science methods and tools to unveil healthcare use of lung cancer patients in a teaching hospital in Spain.

Cruz-Bermúdez JL, Parejo C, Martínez-Ruíz F, Sánchez-González JC, Ramos Martín-Vegue A, Royuela A, Rodríguez-González A, Menasalvas-Ruiz E, Provencio M.

Clin Transl Oncol. 2019 Nov;21(11):1472-1481. doi: 10.1007/s12094-019-02074-2. Epub 2019 Mar 12.

PMID:
30864021
22.

Genomic analyses of microdissected Hodgkin and Reed-Sternberg cells: mutations in epigenetic regulators and p53 are frequent in refractory classic Hodgkin lymphoma.

Mata E, Fernández S, Astudillo A, Fernández R, García-Cosío M, Sánchez-Beato M, Provencio M, Estévez M, Montalbán C, Piris MA, García JF.

Blood Cancer J. 2019 Mar 11;9(3):34. doi: 10.1038/s41408-019-0195-7. No abstract available.

23.

Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group.

Méndez M, Torrente M, Sánchez-Beato M, González-Rincón J, Royuela A, Gómez-Codina J, de la Cruz-Merino L, Rueda A, Llanos M, Quero C, Rodríguez-Abreu D, Gumá J, Monsalvo S, Sabin P, Provencio M.

Hematol Oncol. 2019 Apr;37(2):143-150. doi: 10.1002/hon.2601. Epub 2019 Apr 4.

PMID:
30840776
24.

Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma.

González-Rincón J, Méndez M, Gómez S, García JF, Martín P, Bellas C, Pedrosa L, Rodríguez-Pinilla SM, Camacho FI, Quero C, Pérez-Callejo D, Rueda A, Llanos M, Gómez-Codina J, Piris MA, Montes-Moreno S, Bárcena C, Rodríguez-Abreu D, Menárguez J, de la Cruz-Merino L, Monsalvo S, Parejo C, Royuela A, Kwee I, Cascione L, Arribas A, Bertoni F, Mollejo M, Provencio M, Sánchez-Beato M.

PLoS One. 2019 Feb 25;14(2):e0212813. doi: 10.1371/journal.pone.0212813. eCollection 2019.

25.

Nivolumab-associated digital small-vessel vasculitis in a patient with an advanced renal cell carcinoma.

Franco F, Méndez M, Gutierrez L, Sanz J, Calvo V, Provencio M.

Immunotherapy. 2019 Apr;11(5):379-384. doi: 10.2217/imt-2018-0082.

PMID:
30786844
26.

Treatment of induction in resectable NSCLC with chemotherapy, followed by surgery and erlotinib.

Franco F, Provencio M.

Ann Transl Med. 2018 Nov;6(Suppl 1):S31. doi: 10.21037/atm.2018.09.38. No abstract available.

27.

Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping.

Zugazagoitia J, Ramos I, Trigo JM, Palka M, Gómez-Rueda A, Jantus-Lewintre E, Camps C, Isla D, Iranzo P, Ponce-Aix S, García-Campelo R, Provencio M, Franco F, Bernabé R, Juan-Vidal O, Felip E, de Castro J, Sanchez-Torres JM, Faul I, Lanman RB, Garrido P, Paz-Ares L.

Ann Oncol. 2019 Feb 1;30(2):290-296. doi: 10.1093/annonc/mdy512.

28.

Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group.

Rueda A, Calvo V, Casanova M, Rodriguez-Abreu D, Aguiar D, Llanos M, Alvarez R, Martinez-Banaclocha N, Alfaro J, Quero C, Blasco A, de la Cruz Merino L, Herrero J, García-Arroyo FR, Provencio M.

Leuk Lymphoma. 2019 Jun;60(6):1576-1579. doi: 10.1080/10428194.2018.1542147. Epub 2018 Dec 5. No abstract available.

PMID:
30516082
29.

Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non-Small Cell Lung Cancer.

Karachaliou N, Bracht JWP, Fernandez Bruno M, Drozdowskyj A, Gimenez Capitan A, Moran T, Carcereny E, Cobo M, Domine M, Chaib I, Ramirez JL, Camps C, Provencio M, Vergnenegre A, Lopez-Vivanco G, Majem M, Massuti B, Rosell R.

J Thorac Oncol. 2019 Feb;14(2):304-310. doi: 10.1016/j.jtho.2018.10.168. Epub 2018 Nov 22.

30.

SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018).

Majem M, Juan O, Insa A, Reguart N, Trigo JM, Carcereny E, García-Campelo R, García Y, Guirado M, Provencio M.

Clin Transl Oncol. 2019 Jan;21(1):3-17. doi: 10.1007/s12094-018-1978-1. Epub 2018 Nov 17.

31.

Peritoneal washing is an adequate source for somatic BRCA1/2 mutation testing in ovarian malignancies.

Barquín M, Maximiano C, Pérez-Barrios C, Sanchez-Herrero E, Soriano M, Colmena M, García-Espantaleón M, Tejerina González E, Gutierrez L, Sánchez Ruiz AC, Torrente M, Provencio M, Romero A.

Pathol Res Pract. 2019 Feb;215(2):392-394. doi: 10.1016/j.prp.2018.10.028. Epub 2018 Oct 28.

PMID:
30392916
32.

Cancer-associated fibroblasts modify lung cancer metabolism involving ROS and TGF-β signaling.

Cruz-Bermúdez A, Laza-Briviesca R, Vicente-Blanco RJ, García-Grande A, Coronado MJ, Laine-Menéndez S, Alfaro C, Sanchez JC, Franco F, Calvo V, Romero A, Martin-Acosta P, Salas C, Garcia JM, Provencio M.

Free Radic Biol Med. 2019 Jan;130:163-173. doi: 10.1016/j.freeradbiomed.2018.10.450. Epub 2018 Nov 1.

33.

Using the Lymph2Cx assay for assessing cell-of-origin subtypes of HIV-related diffuse large B-cell lymphoma.

Baptista MJ, Tapia G, Morgades M, Muncunill J, Muñoz-Marmol AM, Montoto S, Gribben JG, Calaminici M, Martinez A, Gonzalez-Farre B, Dlouhy I, González-Barca E, Terol MJ, Miralles P, Alcoceba M, Vall-Llovera F, Briones J, Abrisqueta P, Abella E, Provencio M, García-Ballesteros C, Moraleda JM, Sancho JM, Ribera JM, Mate JL, Navarro JT.

Leuk Lymphoma. 2019 Apr;60(4):1087-1091. doi: 10.1080/10428194.2018.1512711. Epub 2018 Oct 15. No abstract available.

PMID:
30322315
34.

A combination of hydroxytyrosol, omega-3 fatty acids and curcumin improves pain and inflammation among early stage breast cancer patients receiving adjuvant hormonal therapy: results of a pilot study.

Martínez N, Herrera M, Frías L, Provencio M, Pérez-Carrión R, Díaz V, Morse M, Crespo MC.

Clin Transl Oncol. 2019 Apr;21(4):489-498. doi: 10.1007/s12094-018-1950-0. Epub 2018 Oct 6.

PMID:
30293230
35.

Lung cancer in Spanish women: The WORLD07 project.

Garrido P, Viñolas N, Isla D, Provencio M, Majem M, Artal A, Carcereny E, Garcia Campelo R, Lianes P, De La Peñas R, Felip E.

Eur J Cancer Care (Engl). 2019 Jan;28(1):e12941. doi: 10.1111/ecc.12941. Epub 2018 Oct 2.

PMID:
30277293
36.

Consolidation treatment with yttrium-90 ibritumomab tiuxetan after new induction regimen in advanced stage follicular lymphoma: update results from the Spanish Lymphoma Oncology Group trial after a median follow-up of 8.5-years.

Provencio M, Franco F, Gómez-Codina J, Quero Blanco C, Llanos M, Garcia-Arroyo F, de la Cruz L, Gumá J, Delgado JR, Álvarez R, Chacón JI, Royuela A, Rueda A.

Leuk Lymphoma. 2019 Mar;60(3):856-859. doi: 10.1080/10428194.2018.1509322. Epub 2018 Sep 20. No abstract available.

PMID:
30234403
37.

Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib Study.

Kim ES, Kelly K, Paz-Ares LG, Garrido P, Jalal S, Mahadevan D, Gutierrez M, Provencio M, Schaefer E, Shaheen M, Johnston EL, Turner PK, Kambhampati SRP, Beckmann R, Hossain A, John WJ, Goldman JW.

Clin Cancer Res. 2018 Nov 15;24(22):5543-5551. doi: 10.1158/1078-0432.CCR-18-0651. Epub 2018 Aug 6.

38.

Hyperprogression as a distinct outcome after immunotherapy.

Fuentes-Antrás J, Provencio M, Díaz-Rubio E.

Cancer Treat Rev. 2018 Nov;70:16-21. doi: 10.1016/j.ctrv.2018.07.006. Epub 2018 Jul 18. Review.

PMID:
30053725
39.

Profiling Lung Cancer Patients Using Electronic Health Records.

Menasalvas Ruiz E, Tuñas JM, Bermejo G, Gonzalo Martín C, Rodríguez-González A, Zanin M, González de Pedro C, Méndez M, Zaretskaia O, Rey J, Parejo C, Cruz Bermudez JL, Provencio M.

J Med Syst. 2018 May 31;42(7):126. doi: 10.1007/s10916-018-0975-9.

PMID:
29855732
40.

An exploratory, large-scale study of pain and quality of life outcomes in cancer patients with moderate or severe pain, and variables predicting improvement.

Maximiano C, López I, Martín C, Zugazabeitia L, Martí-Ciriquián JL, Núñez MA, Contreras J, Herdman M, Traseira S, Provencio M.

PLoS One. 2018 Apr 3;13(4):e0193233. doi: 10.1371/journal.pone.0193233. eCollection 2018.

41.

Description and Survival of Stage I and II Lung Cancer Patients.

Pérez-Martínez O, Vidal-García I, Montero-Martínez C, Provencio M, Ruano-Ravina A.

Arch Bronconeumol. 2018 Aug;54(8):420-426. doi: 10.1016/j.arbres.2018.02.007. Epub 2018 Mar 16. English, Spanish.

42.

Long-term follow up of Hodgkin lymphoma.

Perez-Callejo D, Zurutuza L, Royuela A, Torrente M, Núñez B, Calvo V, Méndez M, Franco F, Brenes MA, Sánchez JC, Provencio M.

Oncotarget. 2018 Feb 3;9(14):11638-11645. doi: 10.18632/oncotarget.24392. eCollection 2018 Feb 20.

43.

Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.

Jurczak W, Zinzani PL, Gaidano G, Goy A, Provencio M, Nagy Z, Robak T, Maddocks K, Buske C, Ambarkhane S, Winderlich M, Dirnberger-Hertweck M, Korolkiewicz R, Blum KA.

Ann Oncol. 2018 May 1;29(5):1266-1272. doi: 10.1093/annonc/mdy056.

44.

Prognostic value of quantitative ctDNA levels in non small cell lung cancer patients.

Provencio M, Torrente M, Calvo V, Pérez-Callejo D, Gutiérrez L, Franco F, Pérez-Barrios C, Barquín M, Royuela A, García-García F, Bueno C, Garcia-Grande A, Camps C, Massuti B, Sotomayor E, Romero A.

Oncotarget. 2017 Nov 16;9(1):488-494. doi: 10.18632/oncotarget.22470. eCollection 2018 Jan 2.

45.

Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain.

Arriola E, García Gómez R, Diz P, Majem M, Martínez Aguillo M, Valdivia J, Paredes A, Sánchez-Torres JM, Peralta Muñoz S, Barneto I, Gutierrez V, Andrade Santiago JM, Aparisi F, Isla D, Ponce S, Vicente Baz D, Artal A, Amador M, Provencio M.

BMC Cancer. 2018 Jan 30;18(1):106. doi: 10.1186/s12885-018-4004-7.

46.

Analysis of the mutational landscape of classic Hodgkin lymphoma identifies disease heterogeneity and potential therapeutic targets.

Mata E, Díaz-López A, Martín-Moreno AM, Sánchez-Beato M, Varela I, Mestre MJ, Santonja C, Burgos F, Menárguez J, Estévez M, Provencio M, Sánchez-Espiridión B, Díaz E, Montalbán C, Piris MA, García JF.

Oncotarget. 2017 Nov 30;8(67):111386-111395. doi: 10.18632/oncotarget.22799. eCollection 2017 Dec 19.

47.

Mutational profile of primary breast diffuse large B-cell lymphoma.

Franco F, González-Rincón J, Lavernia J, García JF, Martín P, Bellas C, Piris MA, Pedrosa L, Miramón J, Gómez-Codina J, Rodríguez-Abreu D, Machado I, Illueca C, Alfaro J, Provencio M, Sánchez-Beato M.

Oncotarget. 2017 Oct 24;8(61):102888-102897. doi: 10.18632/oncotarget.21986. eCollection 2017 Nov 28.

48.

Twice-daily chemoradiotherapy must still be the choice for patients with limited-stage small-cell lung cancer.

Franco F, Pérez-Callejo D, Provencio M.

J Thorac Dis. 2017 Sep;9(9):2843-2846. doi: 10.21037/jtd.2017.08.113. No abstract available.

49.

PGC-1alpha levels correlate with survival in patients with stage III NSCLC and may define a new biomarker to metabolism-targeted therapy.

Cruz-Bermúdez A, Vicente-Blanco RJ, Laza-Briviesca R, García-Grande A, Laine-Menéndez S, Gutiérrez L, Calvo V, Romero A, Martín-Acosta P, García JM, Provencio M.

Sci Rep. 2017 Nov 30;7(1):16661. doi: 10.1038/s41598-017-17009-6.

50.

Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial.

Abad A, Martínez-Balibrea E, Viéitez JM, Alonso-Orduña V, García Alfonso P, Manzano JL, Massutí B, Benavides M, Carrato A, Zanui M, Gallego J, Grávalos C, Conde V, Provencio M, Valladares-Ayerbes M, Salazar R, Sastre J, Montagut C, Rivera F, Aranda E.

Ann Oncol. 2018 Feb 1;29(2):439-444. doi: 10.1093/annonc/mdx737.

Supplemental Content

Loading ...
Support Center